Clinical trial
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)
NCT02611492 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 30, 2016
- Completion date
- December 31, 2025
- Enrollment
- 265 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
philadelphia chromosome positive adult acute lymphoblastic leukemia